Zydus receives FDA’s ODD for Desidustat for the treatment of beta-thalassemia
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
Orphan drug designation (ODD) by the USFDA for Desidustat, provides eligibility for a potential seven-year marketing exclusivity subject to the USFDA approval
During the quarter, Zydus Wellness completed the acquisition of Comfort Click Limited and its subsidiaries
Senores Pharmaceuticals (SPI) acquired 51% stake in Zoraya Pharmaceuticals
Glenmark will begin distribution in November 2025
Budesonide is indicated for mild to moderate active Crohn's disease involving the ileum and/or the ascending colon in adults and children 8 years of age and olde
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Building on the Merck Foundation’s longstanding commitment to advancing access to high-quality health care, new national initiative supports grants to 11 organizations across the country
Medplus Health Services has reported total income of Rs. 1,696.79 crore during the period ended September 30, 2025
PET sheets are widely recognised for their superior clarity, strength, and barrier properties
Subscribe To Our Newsletter & Stay Updated